MSMonique D. Sterrenburg

Monique D. Sterrenburg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monique D. Sterrenburg has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Hesham Gaber Al-Inany

    Cairo University

    2 shared publications
  • Mohamed Aboulghar

    Egyptian IVF‐ET Center

    2 shared publications
  • Ahmed M Abou-Setta

    Alberta Research Centre for Health Evidence (ARCHE)

    1 shared publication
  • Ahmed M. Abou-Setta

    Alberta Research Centre for Health Evidence (ARCHE) , University of Alberta , Edmonton, AB , Canada

    1 shared publication
  • B. C. J. M. Fauser

    Department of Reproductive Medicine and Gynaecology , University Medical Centre Utrecht , Heidelberglaan 100, Utrecht 3584 CX , The Netherlands

    1 shared publication
  • Bart C. J. M. Fauser

    Department of Reproductive Medicine and Gynecology (M.D.S., F.J.B., M.J.C.E., B.C.J.M.F.) University Medical Centre Utrecht, 3508 GA Utrecht, The Netherlands

    1 shared publication

Latest Publications

  • Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

    by Hesham G Al-Inany, Mohamed Afm Youssef, Mohamed Aboulghar, Frank J Broekmans, Monique D. Sterrenburg, Janine G Smit, Ahmed M Abou-Setta

    Background Gonadotrophin‐releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo‐estrogenic side‐effects, flare‐up, or long down‐regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotropin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimes have been described including multiple‐dose fixed (0.25 mg daily from day six to seven of stimulation), multiple‐dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single‐dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006. Objectives To evaluate the effectiveness and safety of gonadotrophin‐releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycle Search methods We performed electronic searches of major databases, for example Cochrane Menstrual Disorders and Subfertility Group Specialised Register, CENTRAL, MEDLINE, EMBASE (from 1987 to April 2010); and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). Selection criteria Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different agonist versus antagonist protocols in women undergoing IVF or ICSI. Data collection and analysis Two review authors independently assessed trial risk of bias and extracted data. If relevant data were missing or unclear, the authors were contacted for clarification. Main results Forty‐five RCTs (n = 7511) comparing the antagonist to the long agonist protocols fulfilled the inclusion criteria. There was no evidence of a statistically significant difference in rates of live‐births (9 RCTs; odds ratio (OR) 0.86, 95% CI 0.69 to 1.08). There was a statistically significant lower incidence of OHSS in the GnRH antagonist group (29 RCTs; OR 0.43, 95% CI 0.33 to 0.57). Authors' conclusions The use of antagonist compared with long GnRH agonist protocols was associated with a large reduction in OHSS and there was no evidence of a difference in live‐birth rates.


  • Follicular Phase Endocrine Characteristics during Ovarian Stimulation and GnRH Antagonist Cotreatment for IVF: RCT Comparing recFSH Initiated on Cycle Day 2 or 5

    by Christophe Blockeel, Monique D. Sterrenburg, Frank J. Broekmans, Marinus J. C. Eijkemans, Johan Smitz, Paul Devroey, Bart C. J. M. Fauser

    Context: Strategies involving mild ovarian stimulation protocols for in vitro fertilization (IVF) might lessen discomfort to the patient and substantially lower complication rates. Objective: The objective of the study was to compare the follicular-phase endocrine characteristics and follicular development in patients who started recombinant FSH (recFSH) on cycle day (CD) 2 or CD5 in IVF treatment, using GnRH antagonist as comedication. Design: This was a prospective randomized controlled trial in two university centers in Belgium and The Netherlands. Patients: Seventy-six IVF/intracytoplasmic sperm injection patients were included in the study. Interventions: The control group (CD2) received a standard treatment with 150 IU recFSH from CD2, whereas in the study group (CD5), stimulation was started on d 5 of the cycle. The GnRH antagonist was administered daily from CD6 onward in both treatment arms. Main Outcome Measure: Endocrine follicular phase profile during ovarian stimulation was measured. Results: Follicular-phase patterns of gonadotropin and steroid concentrations were found to be comparable in both treatment groups, except for serum estradiol being significantly higher in the CD2 group on d 6 of the cycle (295.6 ± 202.5 ng/liter in the CD2 vs. 102.5 ± 47.9 ng/liter in the CD5 group; P < 0.01) and LH being significantly higher in the CD5 group on d 6 of the cycle (1.7 ± 0.7 IU/liter in the CD2 vs. 5.0 ± 2.1 IU/liter in the CD5 group; P < 0.01). With regard to follicular development, there was no difference in the numbers of small follicles ( 12–14 mm) and large follicles (>14 mm) in both groups. Conclusions: This study shows that the administration of recFSH starting on d 2 or d 5 of the cycle in a GnRH antagonist protocol for IVF/intracytoplasmic sperm injection patients yields a comparable endocrine profile and follicular development. Future studies should focus on the design of more patient-tailored ovarian stimulation protocols.


  • Open Access

    GnRH antagonists are safer than agonists: an update of a Cochrane review

    by Hesham G. Al-Inany, Mohamed A.F.M. Youssef, Mohamed Aboulghar, Frank Broekmans, Monique Sterrenburg, Janine Smit, Ahmed M. Abou-Setta

    GnRH agonists or antagonists can be used to prevent LH surges during ovarian stimulation for assisted reproduction. GnRH agonists down-regulate GnRH pituitary receptors. GnRH antagonists directly and rapidly inhibit gonadotrophin release. In a 2006 systematic review involving 29 trials, the average clinical pregnancy rate was 4.7% lower with GnRH antagonist treatment and the incidence of ovarian hyperstimulation syndrome (OHSS) was 2% lower compared with GnRH agonist treatment ( Al-Inany et al., 2006). The current update includes 45 trials which addressed live birth or ongoing pregnancy rate (OPR) in GnRH antagonist and GnRH agonist protocols among women undergoing assisted reproduction treatment ( Youssef et al., 2011).


  • Open Access

    Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis

    by M. D. Sterrenburg, S. M. Veltman-Verhulst, M. J. C. Eijkemans, E. G. Hughes, N. S. Macklon, F. J. Broekmans, B. C. J. M. Fauser

    The optimal ovarian stimulation dose to obtain the best balance between the probability of pregnancy and the risk of complications, while maximizing cost-effectiveness of in vitro fertilization (IVF) treatment, is yet to be established. A systematic search of the electronic databases PubMed, EMBASE and Cochrane library, from 1984 until October 2009 for randomized controlled trials comparing different doses of recombinant FSH in IVF, was performed. Ten studies (totaling 1952 IVF cycles) were included in the present meta-analysis, comprising patients younger than 39 years with regular menstrual cycle, normal basal FSH levels and two normal ovaries. Comparison was made between studies using a daily dose of 100 versus 200 IU recFSH, and between 150 versus 200 IU recFSH or higher. Although oocyte yield was greater in the >200 IU/day dose group, pregnancy rates were similar compared with lower dose groups. The risk of insufficient response to ovarian stimulation was greatest in the 100 IU/day dose group. The risk of developing ovarian hyperstimulation syndrome was greater in the >200 IU/day dose group. The number of embryos available for cryopreservation was lowest in the 100 IU/day group, but similar comparing the 150 IU/day and the >200 IU/day dose groups. This meta-analysis suggests that the optimal daily recFSH stimulation dose is 150 IU/day in presumed normal responders younger than 39 years undergoing IVF. Compared with higher doses, this dose is associated with a slightly lower oocyte yield, but similar pregnancy and embryo cryopreservation rates. Furthermore, the wide spread adherence to this optimal dose will allow for a considerable reduction in IVF costs and complications.


  • Drugs in reproductive medicine

    by Monique D. Sterrenburg, Nick S. Macklon